Emerging drugs for cystic fibrosis

Bibliography

• The cystic fibrosis genetic analysis consortium. Available from: http://www.genet.sickkids.on.ca/cftr/
   Google Scholar
• Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992;256:774-9
   PubMed Web of Science ®Google Scholar
• Ratjen F. New pulmonary therapies for cystic fibrosis. Curr Opin Pulm Med 2007;13:541-6
   PubMed Web of Science ®Google Scholar
• Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001
   PubMed Web of Science ®Google Scholar
• Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012;487:109-13
   PubMed Web of Science ®Google Scholar
• Alton EW, Boyd AC, Cheng SH, et al. A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Thorax 2013;68(11):1075-7
   PubMed Web of Science ®Google Scholar
• Griesenbach U, Geddes DM, Alton EW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther 2006;13:1061-7
   PubMed Web of Science ®Google Scholar
• UK Cystic Fibrosis Gene Therapy Consortium. Available from: http://www.cfgenetherapy.org.uk/ [Accessed on 12 November 2007]
   Google Scholar
• Griesenbach U, Inoue M, Meng C, et al. Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. Am J Respir Crit Care Med 2012;186:846-56
   PubMed Web of Science ®Google Scholar
• Potash AE, Wallen TJ, Karp PH, et al. Adenoviral gene transfer corrects the ion transport defect in the sinus epithelia of a porcine CF model. Mol Ther 2013;21:947-53
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009;106:18825-30
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72
   PubMed Web of Science ®Google Scholar
• McKone EF, Borowitz D, Drevinek P, et al. Long-term safety and efficacy of investigational CFTR potentiator, VX-770, in subjects with CF [Abstract 204]. Pediatr Pulmonol 2011;46(S34):284
   Google Scholar
• A study of Lumacaftor in Combination with Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT). 2013
   Google Scholar
• Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 2014;13(1):29-36
   PubMed Web of Science ®Google Scholar
• De Boeck K, Paskavitz J, Chen X, Higgins M. Ivacftor, a CFTR potentiator in cystic fibrosis patients who have a non-G551D-CFTR Gating Mutation: Phase 3, Part 1 Results. North American Cystic Fibrosis Conference; Pediatric Pulmonology, Salt Lake City: 2013;48(S36):292 (Abst 241)
   Google Scholar
• Study of Ivacaftor in Subjects with Cystic Fibrosis Who Have the R117H-CFTR Mutation (KONDUCT). 2013
   Google Scholar
• Pilot study testing the effect of ivacaftor on lung function in subjects with cystic fibrosis and residual CFTR function. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/nct01685801
   Google Scholar
• Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012;142:718-24
   PubMed Web of Science ®Google Scholar
• Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012;11:237-45
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011;108:18843-8
   PubMed Web of Science ®Google Scholar
• Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12-18
   PubMed Web of Science ®Google Scholar
• Boyle MP, Bell S, Konstan MW, et al. VX-809, an investigational CFTR corrector, in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508del-CFTR mutation [abstract 212]. Pediatr Pulmonol 2011;46(S34):287
   Google Scholar
• Final Data from phase 2 combination study of VX-809 and Kalydeco (ivacaftor) showed statistically significant improvement in lung function in people with cystic fibrosis who have two copies of the F508del mutation 2013
   Google Scholar
• A Study of Lumacaftor in Combination with Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years adn Older Who re Homozygous for the F508del-CFTR Mutation (TRAFFIC) 2013
   Google Scholar
• Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290:L1117-30
   PubMed Web of Science ®Google Scholar
• Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation. 2013
   Google Scholar
• Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People With Cystic Fibrosis Who Have Two Copies of the F508del Mutation. 2013
   Google Scholar
• Okiyoneda T, Veit G, Dekkers JF, et al. Mechanism-based corrector combination restores DeltaF508-CFTR folding and function. Nat Chem Biol 2013;9:444-54
   PubMed Web of Science ®Google Scholar
• Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010;182:1262-72
   PubMed Web of Science ®Google Scholar
• Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test 1997;1:35-9
   PubMedGoogle Scholar
• Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 2008;105:2064-9
   PubMed Web of Science ®Google Scholar
• Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007;47:430-44
   PubMed Web of Science ®Google Scholar
• Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372:719-27
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011;38:59-69
   PubMed Web of Science ®Google Scholar
• Konstan M, Accurso F, DeBoeck K. Pretreatment data from phase 3 study of ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis [Abstract 232]. Pediatr Pulmonol 2011;46(S34):295
   PubMedGoogle Scholar
• PTC Therapeutics, Inc. Top-line data from phase 3 trial of ataluren in patients with nonsense mutation cystic fibrosis show promising results. 2012. Available from: http://ptct.Client.Shareholder.Com/releasedetail.Cfm?Releaseid=681445
   Google Scholar
• Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52:900-3
   PubMed Web of Science ®Google Scholar
• Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-50
   PubMed Web of Science ®Google Scholar
• Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40
   PubMed Web of Science ®Google Scholar
• Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012;307:2269-77
   PubMed Web of Science ®Google Scholar
• Subbarao P, Stanojevic S, Brown M, et al. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis: a pilot study using inhaled hypertonic saline. Am J Respir Crit Care Med 2013;188(4):456-60
   PubMed Web of Science ®Google Scholar
• Wills PJ, Hall RL, Chan W, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 1997;99:9-13
   PubMed Web of Science ®Google Scholar
• Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: a randomised open-label dose response trial. J Cyst Fibros 2011;10:1-8
   PubMed Web of Science ®Google Scholar
• Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011;38:1071-80
   PubMed Web of Science ®Google Scholar
• Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185:645-52
   PubMed Web of Science ®Google Scholar
• Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 2012;12(4):367-76
   PubMed Web of Science ®Google Scholar
• Caputo A, Caci E, Ferrera L, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 2008;322:590-4
   PubMed Web of Science ®Google Scholar
• Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010;65:51-6
   PubMed Web of Science ®Google Scholar
• Razvi S, Quittell L, Sewall A, et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009;136:1554-60
   PubMed Web of Science ®Google Scholar
• Lambiase A, Raia V, Del Pezzo M, et al. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect Dis 2006;6:4
   PubMed Web of Science ®Google Scholar
• Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-61
   PubMed Web of Science ®Google Scholar
• Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-8
   PubMed Web of Science ®Google Scholar
• Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990;116:714-19
   PubMed Web of Science ®Google Scholar
• Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-87
   PubMed Web of Science ®Google Scholar
• Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100
   PubMed Web of Science ®Google Scholar
• Parkins M, Elborn JS. Tobramycin inhalation powder: a novel drug delivery system for teating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med 2011;5(5):609-22
   PubMed Web of Science ®Google Scholar
• Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72:651-7
   PubMed Web of Science ®Google Scholar
• di Santa a Agnese PE, Andersen DH. Celiac syndrome, chemotherapy in infections of the respiratory tract assocaited with cystic fibrosis of the pancreas; observations with penicillin and drugs of teh sulfonamide group, with special reference to penicillin aerosol. Am J Dis Child 1946;72:17-61
   PubMedGoogle Scholar
• Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009;54:658-70
   PubMed Web of Science ®Google Scholar
• Doring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012;11:461-79
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6
   PubMed Web of Science ®Google Scholar
• Geller DE, Konstan MW, Noonberg S, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects:pharmacokinetics and safety. Pediatr Pulmonol 2007;42:307-13
   PubMed Web of Science ®Google Scholar
• Konstan MW, Flume PA, Kappler M. Safety, efficacy and convenience of Tobramycin Inhalation Powder in cystic fibrosis patients: the EAGER Trial. J Cyst Fibros 2011;10:54-61
   PubMed Web of Science ®Google Scholar
• Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr Pulmonol 2010;46:230-8
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30
   PubMed Web of Science ®Google Scholar
• Galeva I, Konstan MW, Higgins M, et al. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr Med Res Opin 2013;1-35
   Google Scholar
• European MA. Tavanic-summary of product characteristics, labelling and package leaflet. In; 2012. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Tavanic/human_referral_000310.jsp&mid=WC0b01ac05805c516f
   Google Scholar
• Griffith H, Pressler T, Baichen T. Single-dose pharmacokinetics of aerosol mp-376 (levofloxacin solution for inhalation) in custic fibrosis patients. J Cyst Fibros 2008;7:S26
   Google Scholar
• Geller DE, Flume PA, Schwab U. A phase i safety and tolerability and pharmacokinetic study of m-376 (levoflozacin solution for inhalation) in stable systic fibrosis (cf) patients. Pediatr Pulmonol 2008;43:315
   Google Scholar
• Geller DE, Flume PA, Griffith H. Pharmacokinetics and safety of mp-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother 2011;55:2636-40
   PubMed Web of Science ®Google Scholar
• Griffith D, Rock J, Hansen C. Pharmacokinetics and safety of mp-376 (levofloxacin solution for inhalation) in normal healthy volunteers and cystic fibrosis patients. Pediatr Pulmonol 2007;42:303
   Google Scholar
• Geller DE, Flume PA, Staab D, et al. Levoflazacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183:1510-16
   PubMed Web of Science ®Google Scholar
• Sethi R, Miravitlles M, Martinez J. A phase 2 study to evaluate the safety, tolerability and efficacy of levofloxacin inhalation solution (mp-376) administered for 5 days every 28 days to prevent acute exacerbation in high risk copd patients. am J Respir Crit Care Med 2012;185:A3037
   Google Scholar
• MP-376 (Aeroquin™, Levofloxacin for Inhalation) in patients with cystic fibrosis. 2010 - 2013. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01180634?term=MP-376&rank=3
   Google Scholar
• Trial of aeroquin versus tobramycin inhalation solution (tis) in cystic fibrosis (cf) patients. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01270347?term=mp-376&rank=7
   Google Scholar
• Coates C. Performance of PARI eFlow. J Aerosol Med Pulm Drug Deliv 2010;23:114
   PubMed Web of Science ®Google Scholar
• Meers P, Neville M, Malinin V. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008;61:859-68
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Wurtz W. Characterizatrion of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 2008;21:245-54
   PubMed Web of Science ®Google Scholar
• Clancy J. Clinical trials of lipid-associated aerosolized amikcin: the Arikace story. Pediatr Pulmonol 2009;44:109-212
   Google Scholar
• Weers J, Metzheiser B, Taylor G. A gamma scintigraphy study to investigate lung depostion and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv 2009;22:131-8
   PubMed Web of Science ®Google Scholar
• Clancy J, Dupont L, Konstan M, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013;68(9):818-25
   PubMed Web of Science ®Google Scholar
• Bilton D PT, Isabelle F, John Paul C, et al. Phase 3 efficacy and safety data from randomized, multicenter study of liposomal amikacin for inhalation (Arikace) compared with TOBI in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa. North American cystic fibrosis conferenc, Pediatric Pulmonology, Salt Lake City, USA; 2013. p. 290
   Google Scholar
• Schuster A, Haliburn C, Doring G, Goldman M. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreath DPI) in patients with cystic fibrosis: a randomized study. Thorax 2013;68:344-50
   PubMed Web of Science ®Google Scholar
• Dodd M, Webb AK. Understanding non-compliance with treatment in adults with cystic fibrosis. J R Soc Med 2000;93:2-8
   PubMed Web of Science ®Google Scholar
• Kettler L, Sawyer S, Winefield H. Determinants of ahderence in adults with cystic fibrosis. Thorax 2007;57:459-64
   Google Scholar
• Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69
   PubMed Web of Science ®Google Scholar
• Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am J Respir Crit Care Med 2012;185:171-8
   PubMed Web of Science ®Google Scholar
• Milla CE, Chmiel JF, Accurso FJ, et al. Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Sawicki GS, Rasouliyan L, Pasta DJ, et al. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol 2008;43:1117-23
   PubMed Web of Science ®Google Scholar
• Sawicki GS, Rasouliyan L, Ren CL. The impact of MRSA on lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2009;179:734-5; author reply 5
   PubMed Web of Science ®Google Scholar
• Efficacy and safety study of aerovanc for the treatment of persistent MRSA lung infection in cystic fibrosis patients. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01746095
   Google Scholar
• Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997;24:137-42; discussion 59-61
   PubMed Web of Science ®Google Scholar
• Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-82
   PubMed Web of Science ®Google Scholar
• Wanner A, Arce AD, Pardee E. Novel therapeutic uses of alpha-1 antitrypsin: a window to the future. COPD 2012;9:583-8
   PubMedGoogle Scholar
• Brand P, Schulte M, Wencher M, et al. Lung depostition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J 2009;34:354-60
   PubMed Web of Science ®Google Scholar
• Griese M, Latzin P, Kappler M, et al. Alpha1-antitrypsin inhalation reduces airway inflamation in cystic fibrosis patients. Eur Respir J 2007;29:240-50
   PubMed Web of Science ®Google Scholar
• Hansen G, Schuster A, Zubrod C, Wahn V. Alpha 1-Proteinase inhibitorabrogates protolytic and seretagogue activities of cystic fibrosis sputum. Respiration 1995;62:117-24
   PubMed Web of Science ®Google Scholar
• Martin S, Downey D, Bilton D, et al. Safety and efficacy of recombinant alpha1-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006;41:177-83
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337:392-4
   PubMed Web of Science ®Google Scholar
• Taggart C, Coakley R, Greatlly P, et al. Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8. Am J Physiol Lung Cell Mol Physiol 2000;278:33-41
   PubMed Web of Science ®Google Scholar
• Kerem E BS, Strauss P, Jaffe N, et al. Safety/efficacy of inhaled alpha-1 antitrypsin (AAT) in CF: a phase II clinical study. J Cyst Fibros 2009;8:S25
   Google Scholar
• Safety and tolerability trial of inhaled alpha1-proteinase inhibitor (human), hydrophobic chromatography process (alpha-1 HC) in subjects with cystic fibrosis. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01684410?term=inhalation+AND+alpha+1+antitrypsin+AND+cystic+fibrosis&rank=1
   Google Scholar